BriaCell Therapeutics Corp. (BCTX) is making headlines today with a remarkable pre-market price surge of 15.1%, bringing the current pre-market price to $5.78. This increase follows groundbreaking news from the company regarding its innovative treatment approach in metastatic breast cancer.
The surge in BCTX's stock price can be attributed to recent clinical trial results that showcased a positive response from a patient treated with Bria-OTS™, BriaCell's personalized off-the-shelf immunotherapy. In a press release, the company announced that the first patient in the ongoing Phase 1/2a study displayed an unprecedented response, with a lung metastasis resolving after just four doses of the treatment over two months.
This promising result emphasizes the potential of Bria-OTS™ as an effective therapeutic option, especially for patients with limited responses to traditional therapies. Dr. William V. Williams, BriaCell's President and CEO, expressed optimism about the treatment's credibility, stating, "This data supports our hypothesis of personalized immunotherapy with Bria-OTS™, potentially leading to new and effective treatment of metastatic breast cancer."
The company is engaged in a dose escalation study to evaluate the efficacy and safety of Bria-OTS™, which represents a significant advancement in BriaCell's commitment to transforming cancer care. The significant price movement seen in BCTX stock reflects investor optimism following these results, potentially paving the way for further advancements in their treatment programs.
